公开(公告)号：US20140193438A1

公开(公告)日：2014-07-10

申请号：US14203118

申请日：2014-03-10

Applicant: Bristol-Myers Squibb Company

Inventor： Naidu S. Chowdari ,  Sanjeev Gangwar ,  Bilal Sufi

IPC: C07D491/08 ,  A61K31/439 ,  A61K47/48

CPC classification number: C07D491/08 ,  A61K31/439 ,  A61K47/48384 ,  A61K47/6803 ,  C07K16/18

Abstract: Enediyne compounds having a structure according to formula (I), where R0, R2, R3, R4, R5, R6, and R7 are defined herein, can be used in chemotherapeutic drugs, especially in conjugates, for the treatment of diseases such as cancer.

Abstract translation: 具有式（I）结构的烯二烯化合物，其中R 0，R 2，R 3，R 4，R 5，R 6和R 7在本文中定义，可用于化疗药物，特别是缀合物用于治疗疾病如癌症 。

公开(公告)号：US08709431B2

公开(公告)日：2014-04-29

申请号：US13764226

申请日：2013-02-11

Applicant: Bristol-Myers Squibb Company

Inventor： Naidu S. Chowdari ,  Sanjeev Gangwar ,  Bilal Sufi

IPC: A61K39/00 ,  C07D489/12 ,  C07D491/00 ,  C07D498/00 ,  C07D513/00 ,  C07D515/00 ,  A61K31/44 ,  A01N43/42 ,  C07K16/00 ,  C12P21/08

CPC classification number: C07D491/08 ,  A61K31/439 ,  A61K47/48384 ,  A61K47/6803 ,  C07K16/18

Abstract: Enediyne compounds having a structure according to formula (I), where R0, R2, R3, R4, R5, R6, and R7 are defined herein, can be used in chemotherapeutic drugs, especially in conjugates, for the treatment of diseases such as cancer.

Abstract translation: 具有式（I）结构的烯二烯化合物，其中R 0，R 2，R 3，R 4，R 5，R 6和R 7在本文中定义，可用于化疗药物，特别是缀合物用于治疗疾病如癌症 。

公开(公告)号：US11485741B2

公开(公告)日：2022-11-01

申请号：US17043886

申请日：2019-04-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ashok V. Purandare ,  Honghe Wan ,  Liqi He ,  Sanjeev Gangwar ,  Shoshana L. Posy ,  Yam B. Poudel ,  Prasanna Sivaprakasam ,  Naidu S. Chowdari

IPC: C07D487/16 ,  A61K47/60

Abstract: Compounds having a structure according to formula are modulators of TLR7 activity and can be used to treat conditions amenable to treatment by the modulation of TLR7 activity.

公开(公告)号：US10941145B2

公开(公告)日：2021-03-09

申请号：US16890765

申请日：2020-06-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yam B. Poudel ,  Sanjeev Gangwar ,  Prasanna Sivaprakasam ,  Shoshana L. Posy

IPC: C07D473/18 ,  A61P37/04

Abstract: Compounds having a structure according to formula (I) where R1, R2, and R3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

公开(公告)号：US10723736B2

公开(公告)日：2020-07-28

申请号：US16660365

申请日：2019-10-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yam B. Poudel ,  Liqi He ,  Sanjeev Gangwar ,  Shoshana L. Posy ,  Prasanna Sivaprakasam

IPC: C07D473/18 ,  A61P37/04 ,  A61K47/60 ,  A61K47/68

Abstract: Compounds having a structure according to formula (I) where R1 and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

公开(公告)号：US10689382B2

公开(公告)日：2020-06-23

申请号：US16676870

申请日：2019-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Liqi He ,  Sanjeev Gangwar ,  Yam B. Poudel ,  Prasanna Sivaprakasam

IPC: A61K31/52 ,  A61K31/522 ,  C07D473/14 ,  C07D473/18 ,  A61P37/04 ,  A61K47/68

Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R3, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

公开(公告)号：US10508115B2

公开(公告)日：2019-12-17

申请号：US16103619

申请日：2018-08-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Liqi He ,  Sanjeev Gangwar ,  Yam B. Poudel ,  Prasanna Sivaprakasam

IPC: A61K31/52 ,  A61K31/522 ,  C07D473/14 ,  A61P31/14 ,  A61P31/20 ,  C07D473/18 ,  A61P37/04 ,  A61K47/68

Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R3, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

公开(公告)号：US10112975B2

公开(公告)日：2018-10-30

申请号：US15785675

申请日：2017-10-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yong Zhang ,  Ivar M. McDonald ,  Naidu S. Chowdari ,  Tram N. Huynh ,  Robert M. Borzilleri ,  Sanjeev Gangwar

IPC: C07D487/04 ,  C07D519/00 ,  C07K5/062

Abstract: Benzodiazepine dimers having a structure represented by wherein R1 is wherein the variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

公开(公告)号：US20140227295A1

公开(公告)日：2014-08-14

申请号：US14177376

申请日：2014-02-11

Applicant: Bristol-Myers Squibb Company

Inventor： Qiang CONG ,  Heng Cheng ,  Sanjeev Gangwar

IPC: C07K5/117 ,  C07K7/06 ,  A61K47/48

CPC classification number: C07K5/1024 ,  A61K38/05 ,  A61K38/07 ,  A61K47/48246 ,  A61K47/48415 ,  A61K47/48569 ,  A61K47/48592 ,  A61K47/48607 ,  A61K47/48615 ,  A61K47/48638 ,  A61K47/6811 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6861 ,  A61K47/6863 ,  A61K47/6869 ,  C07K5/06 ,  C07K5/06139 ,  C07K5/06165 ,  C07K5/10 ,  C07K5/1016 ,  C07K7/06

Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.

Abstract translation: 其中R 1，R 2，R 3a，R 3b，R 4，R 5，W和n如本文所定义的式（I）的调节素化合物是可用于治疗癌症的抗有丝分裂剂，特别是当与 靶向部分。

公开(公告)号：US11911483B2

公开(公告)日：2024-02-27

申请号：US17126555

申请日：2020-12-18

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yam B. Poudel ,  Sanjeev Gangwar

IPC: A61K47/65 ,  A61K47/64 ,  A61K47/68 ,  A61P35/00 ,  A61K45/06

CPC classification number: A61K47/65 ,  A61K45/06 ,  A61K47/6425 ,  A61K47/6865 ,  A61P35/00

Abstract: Compounds represented by formula (I)




can be used to make antibody-drug conjugates. The conjugates so made are stable in both human and mouse serum, enabling the performance of pre-clinical studies using a mouse model.